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An effective vaccine prioritization process is essential to prevent the many issues that 
currently weaken global vaccination efforts. Identifying challenges associated with vaccine 
development is important when considering which initiatives will provide immunization that is 
effective, affordable, and easy to administer. The process of establishing priorities for vaccine 
development is complicated, though, by the conflicting interests of multiple stakeholders 
involved in the vaccine market. Additionally, uncertainties exist regarding: (1) the resources and 
time required for vaccine development, (2) the expected benefits of development, and (3) the 
anticipated demand for vaccination, further complicating the prioritization process.   
This study proposes a decision-support tool for prioritizing vaccine initiatives through the 
use of mathematical optimization models. The tool will allow a panel of decision makers to 
assess vaccine candidates over multiple criteria with information that is both quantitative and 
qualitative. This assessment will be the result of a methodology that integrates Data 
Envelopment Analysis and the Analytic Hierarchy Process. Ultimately, the decision-support tool 
will allow researchers and funding agencies to determine which vaccine initiatives should be: 
more effective, affordable, profitable, reliable, easier to use and store, and more suitable to the 
needs of multiple populations from diverse locations and having multiple logistic needs. 
 
1. Introduction 
With numerous vaccine initiatives in various stages of development around the world, 
government funding agencies, foundations, vaccine producers, and researchers are faced with the 
challenge of determining which initiatives should be fostered and receive additional attention and 
financial support. For these organizations, a renewed focus on developing priority-setting 
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strategies for new vaccine development is timely and critical. This is evident in the 2010 
National Vaccine Plan, a report by the U.S. government with goals for enhancing all aspects of 
vaccines and vaccination. In the report, strategies are listed to guide disease prevention and 
improve vaccination, including: “develop and implement a process for prioritizing and 
evaluating new vaccine targets of domestic and global public health importance” [1]. The 
Institute of Medicine (IOM) has also targeted vaccine prioritization as an integral part in the 
design of a national and global vaccine development strategy. Despite a few efforts by the IOM 
to address the vaccine prioritization problem, to date, no universally accepted method or model 
exists to guide these important decisions [2].  
Prioritizing vaccine initiatives can provide a framework for organizations or stakeholders 
in the vaccine market to discuss investment alternatives and converge toward solutions that 
satisfy most parties. Additionally, allocating proper resources to a vaccine initiative can reduce 
the time it spends in development, allowing it to provide immunization to the public sooner.  
Increased interests, efforts, and collaborations related to vaccine-preventable diseases are adding 
to the need for vaccine prioritization. Figure 1 shows the market attractiveness of vaccine 
investments over the last 30 years. A renewed interest in vaccine development is evident, with a 




Figure 1: Historical attractiveness of vaccine investments. 
SOURCE: Institute of Medicine, 2012 [2]. 
 
For any organization choosing to invest in the development of a vaccine initiative, there 
are a number of factors that make the decision to select one project over another challenging. 
Varying public health environments, social and economic infrastructures, political conditions, 
and climates, for example, can have a significant impact on the effectiveness and profitability of 
an initiative. These circumstances can vary significantly around the world and can heavily 
influence a vaccine initiative’s likelihood of success. Additionally, decision makers can face 
uncertainty regarding: the expected length of time for the vaccine to become licensed for use, the 
vaccine initiative’s financial viability, and the logistic challenges associated with vaccine 
delivery. Other aspects that influence vaccine prioritization include: the magnitude of disease 
burden, public perception of the disease and the need for its control, whether the disease has the 
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potential to cause epidemics and pandemics, whether the vaccine has characteristics that are 
attractive for use in developing countries, and the cost-effectiveness of the vaccine [3].  
Key stakeholders of the vaccine market assess the importance of vaccine criteria 
differently, and while organizations’ internal mechanisms to set priorities are not well known or 
publicized, information has been gathered about the varying priorities of the public sector, 
private sector, and non-governmental groups. Manufacturers, for example, favor the 
development of vaccines that promise high returns and involve the use of currently available 
technologies.  Non-governmental organizations such as UNICEF, GAVI, and PAHO, on the 
other hand, are interested in expanding immunization in developing countries and developing 
vaccines that are inexpensive, easy to distribute, and do not require the use of expensive cold 
chains. Furthermore, different governments (from developing and industrialized nations) are 
interested in the development of vaccines that target diseases specific to their regions.  
An effective vaccine prioritization process will bring together government agencies, 
vaccine manufacturers, humanitarian groups, and other organizations invested in the 
development of vaccines, allowing them to collectively identify vaccine priorities that best 
represent everyone’s interests or provide the least level of conflict. In this thesis, the 
development of an optimization based heuristic is proposed that considers the interests of 
multiple stakeholders to prioritize vaccine candidates that are at different developmental stages 
and target different diseases. Moreover, a heterogeneous group of decision makers is assumed 
with different interests and levels of expertise. Therefore, vaccine prioritization is addressed as a 
multiple criteria decision making (MCDM) problem, involving multiple decision makers who 
base their decisions on both quantitative and qualitative information. The next section describes 
previous attempts at prioritizing vaccine initiatives. 
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2. Previous Vaccine Prioritization Efforts 
The Institute of Medicine, aware of the difficulty associated with vaccine prioritization, 
established three committees over the last 30 years to address the vaccine prioritization problem. 
In 1985, the Institute of Medicine (IOM) published its first report on vaccine prioritization: 
“New Vaccine Development: Establishing Priorities: Volume 1, Diseases of Importance in the 
United States” [4]. Part one of a two-part study, this report aimed to help the National Institute of 
Allergy and Infectious Diseases (NIAID) establish priorities for accelerated vaccine 
development. The committee behind the report was charged with developing a decision-making 
framework to prioritize vaccine candidates for the US population. In addition, the committee was 
asked to evaluate the model’s ability to set priorities for vaccines needed by technologically less 
developed nations, and modify the model to rank potential vaccines for international use. The 
committee’s findings relative to the international aspects of vaccine development appeared in 
part two of the study: “New Vaccine Development: Establishing Priorities: Volume 2, Diseases 
of Importance in Developing Countries” [5].  
The method used by the committee to rank vaccine initiatives was based on a quantitative 
model in which vaccine candidates were ranked according to two criteria: (1) expected health 
benefits measured by the reduction of morbidity and mortality, and (2) expected net savings of 
health care resources. A measurement system based on infant mortality equivalents (IMEs)1 was 
used to compare the health impacts of a disease versus the potential benefits of a vaccine. 
Estimates and judgments by experts were also used when information was incomplete. The 
                                                             




committee adopted a flexible format so that new candidate vaccines could be assessed similarly 
or current candidate vaccines could be reassessed with new data.  
Since the time the report was published, analytical techniques have advanced and other 
metrics have proven to be better measures of health valuation. In addition, the epidemiological 
data used to compare diseases was variable in quality and in some cases, completely absent. This 
created a serious impediment to the development of a comprehensive prioritization scheme, 
leading the IOM to create a second committee in 2000 to address the same problem.   
The 2000 report, “Vaccines for the 21st Century” [6], used an efficiency measure for 
deriving its priorities based on the incremental cost per incremental quality adjusted life year 
gained by vaccination ($/QALY). Using this measure, initiatives were grouped into one of four 
categories. The highest priority, Level I, was designated for vaccine programs projected to save 
money and increase the number of QALYs. Vaccine programs that did not save money were 
grouped into the remaining three categories based on the efficiency of the investment. Level II 
included candidates whose $/QALY was less than $10,000, Level III included candidates for 
which $/QALY ranged between $10,000 and $100,000, and Level IV was for candidates whose 
$/QALY was greater than $100,000. 
Like the 1985-1986 IOM model, one weakness of the 2000 IOM model was that it only 
considered a single attribute to propose vaccine priorities. Additionally, the 2000 model did not 
provide a method for choosing between vaccine initiatives with equal QALYs when one targeted 
a minor form of illness affecting a large portion of the population, and the other targeted a 
disease with a small number of cases but high mortality and the potential for large social 
disruption. An additional shortcoming of the 2000 model was that it only focused on vaccine 
candidates for the US market.  
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The IOM’s most recent attempt at addressing the vaccine prioritization problem is 
currently in development and is the focus of the report: “Ranking Vaccines: A Prioritization 
Framework: Phase I: Demonstration of Concept and a Software Blueprint” [2]. For this recent 
modeling strategy, the committee limited its scope to models that consider multiple attributes; 
the committee recognized that the narrow range of attributes used to prioritize vaccines in the 
previous IOM studies significantly limited their value and applications. The three multi-attribute 
approaches that the committee reviewed were: mathematical programming, multi-attribute utility 
theory, and the analytic hierarchy process. These approaches were evaluated against four criteria: 
transparency, axiomatic foundation, priority scaling, and sensitivity analysis. Ultimately, multi-
attribute utility theory was chosen for the foundation of the committee's work because it provides 
weights and data that are available for all users to see and use, independence from irrelevant 
alternatives (IIA), scaling that can be used for an ordinal ranking, and the ability to conduct 
sensitivity analyses on results [2].  
The current committee's model improves upon the previous two by including multiple 
attributes that address the varied interests of the public sector, private sector, and non-
governmental groups. However, as mentioned in the “2010 National Vaccine Plan” [1], 
collaboration between stakeholders is an important part of establishing and understanding 
priorities for development. This is a major weakness of the new model, which rather than 
promote collaboration, allows users to create priorities that result solely from the application of 
their own criteria or interests. The fact that the model only considers a single decision maker’s 
preferences ignores the idea that vaccine prioritization should reflect the perspectives of multiple 
stakeholders. Therefore, despite the IOM's efforts, there is still a need for a prioritization model 
that considers the individual interests of stakeholders but also encourages collaboration between 
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them. The prioritization model, in accompaniment with stakeholder input, should be able to 
generate a vaccine ranking that best addresses the conflicting interests of all stakeholders. This is 
the focus of the model proposed in the following section.   
 
3. Methodology  
3.1 Overview 
The overall goal of this project is to develop a mathematical optimization model that 
derives a vaccine priority ranking using quantitative and qualitative criteria and the preferences 
of multiple stakeholders. The model is designed to complement the IOM’s current prioritization 
effort. The proposed algorithmic methodology integrates Data Envelopment Analysis (DEA) 
with the Analytic Hierarchy Process (AHP). This method has each individual in a panel of 
decision makers compare: the qualifications of their peers for assessing vaccine initiatives, how 
well each criteria satisfies the goal, and how well each initiative performs with respect to each 
criteria. Pairwise comparison matrices for the decision makers, criteria of evaluation, and 
initiatives with respect to each criterion are derived using the AHP framework. DEA is then used 
to calculate the optimal weight of each decision maker, the optimal weight of each criteria of 
evaluation, and the optimal weight of each initiative with respect to each criteria of evaluation. 
The optimal weights are then used to calculate the relative priority of each initiative.  
3.2 AHP 
Developed by Saaty in the 1970s, the Analytic Hierarchy Process (AHP) helps decision 
makers identify alternatives that best suit their interests [7]. The ranking/selection of a set of 
alternatives is done with respect to an overall goal, which is broken down into a set of criteria. 
Figure 1 shows the basic hierarchical structure of an AHP problem.  
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Figure 2: AHP hierarchical structure 
The AHP provides a comprehensive and rational framework for representing and 
quantifying the elements of decision problems, relating those elements to overall goals, and 
evaluating alternative solutions. Applying the AHP to a decision problem involves four steps: 1) 
structuring the problem into a hierarchical model, 2) comparing elements of the problem to one 
another to generate pairwise comparison matrices, 3) calculating the weight or priority of each 
element in the hierarchy, and 4) aggregating the weights across various levels to obtain the final 
weights of the alternatives. (See [8].)  
Pairwise comparison matrices are an integral part of the AHP, indicating how much more 
important one objective might be than another. Let  
                                                                     A =          = [
       
   
       
]                                                      (1)   
be a pairwise comparison matrix for a single decision maker. The entry in row i and column j of 
A indicates how much more important objective i is than objective j, with    = 1 for all i and    = 
1/    for j ≠ i. How to calculate priorities from a pairwise comparison matrix has been the focus 
of several studies, with techniques aimed at deriving a priority vector including: the eigenvector 
method [9], the weighted least-square method (WLSM) [10], the logarithmic least square method 

















In 2006, Ramanathan [13] developed a method that uses data envelopment analysis 
(DEA) for generating local weights of alternatives from pairwise comparison matrices in the 
AHP. DEA is a linear programming based approach used to determine the productive efficiency 
of a system or decision-making-unit (DMU) (e.g., a university, hospital, or restaurant) by 
comparing how well the DMU converts inputs into outputs. The DMU that produces the largest 
amount of outputs by consuming the least amount of inputs is considered to have an efficiency 
score of one. The efficiencies of the other DMUs are obtained relative to the efficient DMU, and 
are assigned efficiency scores between zero and one [8]. Ramanathan’s method, referred to as 
DEAHP, considers each criterion or alternative in a pairwise comparison matrix as a DMU. The 
row elements of the pairwise comparison matrix are viewed as the outputs of the DMUs, and a 
dummy input with a value of one is used to build a model that calculates the efficiency score for 
each DMU. The efficiency scores are then used as the local priorities of the DMUs, whether they 
are decision criteria or alternatives.  
The DEAHP method succeeds in producing true weights for perfectly consistent pairwise 
comparison matrices, but was criticized by Wang et al [14] for not being able to produce rational 
weights for inconsistent pairwise comparison matrices. In addition, Wang et al [14] proved that 
the DEAHP may also produce illogical results for pairwise comparison matrices with satisfactory 
consistency. As a result, Wang and Chin [15] introduced a new DEA methodology in 2009. 
3.4 DEA Methodology for Priority Determination in the Group AHP 
Wang and Chin’s DEA methodology [15] is aimed at deriving the best local priority 
vector from a pairwise comparison matrix or, for the group AHP, the best local priority vectors 
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from a group of pairwise comparison matrices, regardless of whether they are perfectly 
consistent or inconsistent. 
Let 
                                                         =      
   
   
 = [
   
   
    
   
   
   
   
    
   
]                                                          (2) 
be a pairwise comparison matrix provided by the kth decision maker (DMk) (k = 1,…, m), 
where     
    is the kth decision maker’s assessment of how important objective i is relative to 
objective j, and m is the number of decision makers.  In addition, let hk > 0 be the decision 
maker’s relative importance weight satisfying  ∑   
 
     , and    ,…,    be the decision 
variables. The following model is solved for each wi (i = 1,…,n) to obtain the best relative local 
priorities of the n criteria or alternatives under group decision making. Subscript zero represents 
the decision criterion or alternative under evaluation, namely DMU0:  
                                              Maximize      = ∑  ∑      
   
   
 
   
 
                                                            (3) 
Subject to {
∑  ∑ ∑      
   
      
 
   
 
   
 
   
∑  ∑      
   
   
 
   
 
                   
                   
  
After the best local priorities for both criteria and alternatives have been derived by the 
DEA methodology, the final weight of each decision alternative can be computed using the 
simple additive weighting (SAW) method [9]. Let   , …,    be the best local priorities of the m 
decision criteria and    , …,     be the best local priorities of the n decision alternatives with 
respect to the jth criterion (j = 1,…, m). Equation (4) can be used to calculate the final weight of 
each decision alternative.   
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                                            Final weight of Alternative    =   ∑      
 
                                              (4) 
The above methodology is effective in assessing the value of different alternatives, given 
the assignment of the decision maker weights is correct. Decision maker weights are a) 
determined by an outside decision maker, or b) agreed upon by the decision makers involved in 
the decision making process. For certain group decision making problems, though, there might 
not be any individuals outside of the problem who are qualified to assign decision maker 
weights, or if a group decision making problem is highly classified, having an  outside decision 
maker assign decision maker weights is not an option. When decision makers must work 
together to identify their weights, they must discuss their qualifications for making the decision 
with each other. This can be an impractical and even inconvenient conversation to have, 
especially when members of the group have to identify who among them is least qualified to 
address the problem. A method for calculating decision maker weights using the members of the 
group in an anonymous manner is essential to preserving the integrity of the group decision 
making process.  
We propose to adapt the DEA methodology proposed by Wang and Chin [15] to address 
the vaccine prioritization problem. To do this, we will expand Wang and Chin’s model for group 
decision making to calculate not only the local priorities of the criteria and alternatives, but also 
the weights of the decision makers, whose inputs will be used to provide feedback about 
stakeholder preferences and priorities. The following section reviews the proposed methodology. 
3.5 Comprehensive DEA Methodology for Priority Determination in the Group AHP 
Consider a problem where d decision makers must establish the relative priority of p 
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]                                                          (5) 
be a pairwise comparison matrix provided by the kth decision maker    ) (k = 1,…, d), where 
     
    is the kth decision maker’s assessment of how qualified decision maker i is relative to 
decision maker j for assessing the given problem. The linear programming model in (6) is solved 
for each    (i = 1,…,d) to obtain the weights of the d decision makers involved in group decision 
making: 
 Maximize       = ∑  ∑     
   
   
 
   
 
                                                       (6) 
Subject to {
∑  ∑ ∑     
   
      
 
   
 
   
 
   
∑  ∑     
   
   
 
   
 
                   
                   
 
For the model (6),    is the relative weight or score for decision maker i and    is the 
score of decision maker j with respect to decision maker i. In addition, h is the initial weight of 
each decision maker and is equal to 1/d. The first constraint requires the sum of the output values 
with respect to each decision maker to equal one. The second constraint is a product of Saaty’s 
eigenvector method [9].  
Next, let 
                                                         =      
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]                                                            (7) 
be a pairwise comparison matrix provided by the kth decision maker where      
    is the kth 
decision maker’s assessment of how important criteria i is relative to criteria j in satisfying the 
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goal. The linear programming model in (8) is solved for each CRi (i = 1,…,c) to obtain the 
weights of the c criteria related to the given problem: 
Maximize       = ∑  ∑      
   
   
 
   
 
                                                       (8) 
Subject to {
∑  ∑ ∑      
   
      
 
   
 
   
 
   
∑  ∑      
   
   
 
   
 
                   
                   
 
For the model (8),     is the relative weight or score for criterion i and    is the score of 
criterion j with respect to criterion i. In addition,    is the weight of each decision maker as 
calculated by model (6). The first constraint requires the sum of the output values with respect to 
each criterion to equal one. The second constraint is a product of Saaty’s eigenvector method [9]. 
Now, let  
                                                        =       
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]                                                           (9) 
be a pairwise comparison matrix provided by the kth decision maker where       
    is the kth 
decision maker’s assessment of how project i compares to project j with respect to criteria l. The 
linear programming model in (10) is solved for each PCRil (i = 1,…,p. l = 1,…,c.) to obtain the 
weight of each project with respect to the each criteria: 
                        Maximize         = ∑  ∑       
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For the model (10),       is the relative weight or score for project i with respect to 
criterion l and    is the score of project j with respect to criterion l with respect to the project-
criterion being evaluated (project i with respect to criterion l). In addition,    is the weight of 
each decision maker as calculated by model (6). The first constraint requires the sum of the 
output values with respect to each project-criterion to equal one. The second constraint is a 
product of Saaty’s eigenvector method [9]. 
Lastly, the final weight of each initiative can be computed using the simple additive 
weighting (SAW) method [9]. Let    , …,     be the best local priorities of the c decision 
criteria and      , …,       be the best local priorities of the i decision alternatives with respect 
to the lth criterion (l = 1,…, c). Equation (4) can be used to calculate the final weight of each 
decision alternative.   
                                            Final weight of Alternative    =   ∑         
 
                                         (11) 
 
3.6 Arrow’s Impossibility Theorem 
 According to Arrow’s impossibility theorem [16], when voters have three or more 
distinct alternatives, no rank order voting system can convert the ranked preferences of 
individuals into a community-wide ranking while also meeting the following criteria:  
- If every voter prefers alternative A to alternative B, then the group prefers A to B. 
- If every voter prefers alternative A to alternative B, then any change in preferences that 
does not affect this relationship must not affect the group preference for A over B. This 
requirement is also known as “independence from irrelevant alternatives” (IIA).  
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- There are no dictators; no single voter possesses the power to always determine the 
group’s preference. 
The Comprehensive DEA Methodology for Priority Determination in the Group AHP 
(CDEAGAHP) is a rank-order system that was designed to satisfy the first two criteria while 
allowing decision makers to have different weights of influence over the decision-making 
process. If every voter prefers alternative A to alternative B, then the group ranking will have 
alternative A ranked above alternative B. If an alternative is eliminated from consideration, then 
the new ordering for the remaining alternatives will be equivalent to the original ordering minus 
the eliminated alternative (IIA). Lastly, the CDEAGAHP allows a decision maker to have more 
weight than other decision makers by applying the AHP and DEA to derive weights based on 
peer evaluations.  
An illustrative example that demonstrates an application of the Comprehensive DEA 
Methodology for Priority Determination in the Group AHP (CDEAGAHP) is explained in 
Appendix A. The following section applies the methodology to a vaccine prioritization problem.  
 
4. Vaccine Prioritization Using the Comprehensive DEA Methodology for 
Priority Determination in the Group AHP 
Data was gathered to apply the Comprehensive DEA Methodology for Priority 
Determination in the Group AHP (CDEAGAHP) to a vaccine prioritization problem with five 
decision makers evaluating ten vaccine candidates against ten criteria. For the five decision 
makers, two were chosen to represent the interests of the public sector, two were chosen to 
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represent the interests of the private sector, and one was chosen to represent the interests of non-
governmental organizations. These decision makers are listed in Table 10.  
Table 10: Vaccine Example Decision Makers 
Decision Maker Sector 
Health Agency Representative Pubic 
Public Health Unit Representative Public 
Vaccine Industry Representative Private 
Biopharmaceutical Industry Representative Private 
International Vaccine Initiative Representative Non-governmental Organization 
 
Ten criteria were chosen for the experiment that are similar to some of the 29 criteria 
used in the 2012 IOM model. Criteria were chosen to capture the health, economic, 
demographic, scientific, business, and programmatic considerations associated with vaccine 
development. The ten criteria are listed in Table 11.  
 
Table 11: Vaccine Example Criteria 
Criterion Definition 
Target Population Vaccine targets a disease that affects a 
population of interest  
Cost-Effectiveness $/QALY gained 
Incident Cases Prevented Per Year Through 
Vaccination 
The number of incident cases of disease 
prevented in one year 
Total Development Costs Sum of development costs 
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Potential to Improve Delivery Methods Vaccine development has the potential to 
improve delivery methods or stimulate novel 
approaches to deliver vaccines 
Premature Deaths Averted Per Year Through 
Vaccination 
The number of deaths due to disease 
prevented in one year 
QALYs Gained Net increase in QALYs gained in the 
population vaccinated 
Reduces Challenges Relating to Cold Chain 
Requirements 
Vaccine development has the potential to 
stimulate novel approaches to mitigate the 
challenges relating to cold-chain storage and 
related packaging.  
Healthcare Cost Reduction Health care costs saved 
Time to Licensure  The estimated length of time until successful 
licensure 
 
For the vaccine candidates, ten were chosen as a subset of the 26 vaccine candidates that 
were used for evaluation in “Vaccines for the 21
st
 Century” [6].  The ten vaccine candidates are: 
‘Chlamydia’, ‘Group A Streptococcus’, ‘Hepatitis C’, ‘Human Papillomavirus’, ‘Influenza’, 
‘Melanoma’, ‘Multiple Sclerosis’, ‘Neisseria Gonorrhea’, ‘Rheumatoid Arthritis’, and 
‘Rotavirus’.   
In an ideal situation, a decision like this would involve actual representatives from 
various organizations who could assess each other, the criteria, and the vaccine candidates with 
respect to the criteria. First, each decision maker would rank all of the decision makers, including 
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him or herself, in order of ability to prioritize vaccine candidates. For the ranking, the first 
position would be for the decision maker with the most ability to prioritize vaccine candidates, 
while the last position would be for the decision maker with the least ability to prioritize vaccine 
candidates. If someone thought that two or more decision makers were equal in rank, they could 
rank them in the same position. Before these rankings would occur, though, each decision maker 
would have the opportunity to review the CV’s of the other decision makers to gain an 
understanding of their experience with vaccine development.  
After ranking the decision makers, each decision maker would then rank the criteria of 
evaluation in order of importance for prioritizing vaccine candidates. For the ranking, the first 
position would be for the criterion that the decision maker thinks is most important to consider 
when prioritizing vaccine candidates, while the last position would be for the criterion that the 
decision maker thinks is least important to consider when prioritizing vaccine candidates. If a 
decision maker considered two or more criteria to be equal in performance, they could rank them 
in the same position.  
Lastly, in an ideal situation, the decision makers would rank the vaccine candidates in 
order of preference for the qualitative criteria (“Target Population”, “Potential to Improve 
Delivery Methods”, and “Reduces Challenges Relating to Cold Chain Requirements”). For these 
rankings, the first position would be for the vaccine candidate that the decision maker thought 
best satisfied the criterion, while the last position would be for the vaccine candidate that the 
decision maker though least satisfied the criterion. If a decision maker felt that two or more 




Given that this is a derived experiment, assumptions were made about how the decision 
makers might assess each other, the criteria, and the vaccine candidates with respect to the 
qualitative criteria. The rankings that were created for each decision maker were used to generate 
the pairwise comparison matrices for the model. The pairwise comparison matrices were created 
according to the following rules: 1)     is an integer valued 1-10, 2)     = 1/   , 3)    = 1 for all i, 
3) if the rank of option i, (  ), and the rank of option j, (  ), are equal, then elements     and     
equal one, 4) if    >   , then aij equals (  –   + 1).  
Typically, decision makers would create pairwise comparison matrices themselves rather 
than record rankings of the decision makers, criteria, and alternatives, but constructing pairwise 
comparison matrices is a cumbersome task for decision makers when more than a few criteria are 
considered. In the case where actual decision makers would be using this model, it was decided 
that it would be easier for decision makers to rank their preferences so pairwise comparison 
matrices could be generated from those rankings.  
 For a quantitative criterion, alternatives are ranked according to how they perform with 
respect to that criterion. For the quantitative criteria “QALYs Gained”, “Savings of Vaccine 
Use”, “Incident Cases Prevented Per Year”, and “Premature Deaths Averted Per Year”, the 
vaccine candidates were ranked in descending order. For the quantitative criteria “Time to 
Licensure”, “Total Development Costs”, and “Cost-Effectiveness”, the vaccine candidates were 
ranked in ascending order. The resulting rankings were then used to generate the appropriate 
pairwise comparison matrices for all of the decision makers. Table 12 shows the values 
associated with each vaccine initiative for the seven quantitative criteria. 
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Note. Data for ‘Cost-Effectiveness’, ‘Development Costs’, ‘QALYs Gained’, ‘Savings of Vaccine Use’, and ‘Time to Licensure’ from 
“Vaccines for the 21
st
 Century” [6]. 
a. "Global Health Observatory Data Repository." Cause-specific Mortality, 2008: WHO Region by Country. N.p., n.d. Web. 
<http://apps.who.int/gho/data/node.main.887?lang=en>. 
b. "Influenza (Seasonal)." WHO. N.p., n.d. Web. <http://www.who.int/mediacentre/factsheets/fs211/en/>. 
c. Parashar, Umesh D., et al. "Global mortality associated with rotavirus disease among children in 2004." Journal of Infectious 
Diseases 200.Supplement 1 (2009): S9-S15. 
d. Carapetis, Jonathan R. "The current evidence for the burden of group A streptococcal diseases." Geneva: World Health 
Organization (2004): 1-57. 
e. "Prevalence and Incidence of Selected Sexually Transmitted Infections." WHO. N.p., n.d. Web. 
<http://whqlibdoc.who.int/publications/2011/9789241502450_eng.pdf>. 
f. "Hepatitis C." WHO. N.p., n.d. Web. <http://www.who.int/mediacentre/factsheets/fs164/en/>. 
g. "Global Health Observatory Data Repository." Incidence: WHO Region by Country. N.p., n.d. Web. 
<http://apps.who.int/gho/data/node.main.903?lang=en>. 
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Table 13 shows the weight assigned to each decision maker as determined by the linear 
programming model in (6).  
Table 13: Vaccine Example Decision Maker Weights 
Decision Maker Weight 
Public Health Unit 
Representative 
0.247393 
Health Agency Representative 0.217927 
Vaccine Industry Representative 0.1999291 







Table 14 shows the weight assigned to each criterion as determined by the linear 
programming model in (8). 
Table 14: Vaccine Example Criterion Weights 
Criterion Weight 
Prevented Deaths 0.154938 
Incident Cases 0.138406 
Cost Effectiveness 0.124149 
Cold Chain 0.113343 
QALYs Gained 0.111973 




Time to Licensure 0.0862401 
Delivery Methods 0.0726194 
Priority Population 0.0552014 
 
Table 15 shows the ranking of vaccine candidates produced by the linear programming 
model in (10).  
Table 15: Model Vaccine Candidate Ranking 




Group A Strep 0.106 
HPV 0.1032 
Arthritis 0.097 
Hepatitis C 0.09299 




The ranking suggests that the top three vaccine candidates are ‘Influenza’, ‘Rotavirus’, 
and ‘Chlamydia’. This ranking is consistent with the quantitative data associated with these 




Lastly, the k-means clustering algorithm [17] was used to sort the vaccine candidates into 
clusters and identify which vaccine candidates are similar in overall performance with respect to 
the final ranking. Tables 16 through 19 show the clusters that result from applying the k-means 
algorithm with k = 2 to k = 5.  
Table 16: Vaccine Example k-means Clustering: k=2 




Group A Strep 0.106 
HPV 0.1032 
Arthritis 0.097 
Hepatitis C 0.09299 













Table 17: Vaccine Example k-means Clustering: k=3 




Group A Strep 0.106 
HPV 0.1032 
Arthritis 0.097 
Hepatitis C 0.09299 




Table 18: Vaccine Example k-means Clustering: k=4 




Group A Strep 0.106 
HPV 0.1032 
Arthritis 0.097 
Hepatitis C 0.09299 






Table 19: Vaccine Example k-means clustering: k=5 




Group A Strep 0.106 
HPV 0.1032 
Arthritis 0.097 
Hepatitis C 0.09299 




Sorting vaccine candidates into clusters is consistent with the idea that there is not 
enough precision to decisively state that one vaccine candidate is better than another. For this 
reason, vaccine candidates should be sorted into groups of similar performance, similar to how 
hotels are grouped according to star ratings or countries are grouped according to credit ratings. 
Review of the clusters can be used to identify where significant and insignificant differences 
exist among vaccine candidates. For instance, the clustering of the vaccine candidates above 
suggests that there is not a significant difference between the rankings of ‘Chlamydia’ and 
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‘Rotavirus’, but there is a significant difference between the rankings of these two vaccine 
candidates and ‘Influenza’. 
 
5. Sensitivity Analysis 
The goal of sensitivity analysis is to understand how changes in a problem’s parameters 
affect the problem’s solution. In the case of the vaccine prioritization problem, it is important to 
understand how changes in the decision maker’s preferences might affect the final ranking of 
alternatives. Consider the objective function of model (6): 
 
   = ∑  ∑     
   
   
 
   
 
               
 
For this problem, it is important to know how a decision maker’s assessment of his/her 
fellow decision makers can change without affecting the final ranking of alternatives. Using 
sensitivity analysis, the objective function coefficient ranges were determined; within these 
ranges, the current basis remains optimal. For this problem, that provides the range of ∑     
    
    
for each   . This range must be divided by h to determine how the summation of the decision 
makers’ assessments (∑    
    
   ) can vary when comparing decision maker   to decision maker  . 
Table 12 shows the range in which ∑    
    
   can vary for each  ,  .  
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Table 12: Objective Function Coefficient Ranges 
Decision Makers 
j = Health Agency j = Public Health j= Vaccine Industry 
∑    
    
            
Lower Bound 
∑    
    
     
Upper Bound 
∑    
    
            
Lower Bound 
∑    
    
     
Upper Bound 
∑    
    
            
Lower Bound 
∑    
    
     
Upper Bound 
i = Health Agency 4.8725 5.78 -5.00E+100 4.624 6.675 21.195 
i = Public Health 5.415 6.685 -5.00E+100 5.57 7.925 32.235 
i = Vaccine Industry 4.631 31.815 4.347 35.01 -5.00E+100 5.77 
i = BiopharmIndustry 3.6505 44.575 3.4355 52.25 4.4285 5.00E+100 
i = InternationalVacInit 4.427 5.19 4.6505 26.7 6.605 24.77 
 
Table 12: Objective Function Coefficient Ranges (cont.) 
Decision Makers 
j = BiopharmIndustry j = InternationalVacInit 
∑    
    
            
Lower Bound 
∑    
    
     
Upper Bound 
∑    
    
            
Lower Bound 
∑    
    
     
Upper Bound 
i = Health Agency 7.415 21.555 5.67 23.9 
i = Public Health 8.845 29.855 6.77 87.4 
i = Vaccine Industry 5.64 8.19 5.11 45.865 
i = BiopharmIndustry -5.00E+100 5.64 3.993 68.65 
i = InternationalVacInit 7.365 21.33 -5.00E+100 5.625 
 
Although ∑    
    
    can vary within these ranges, the final ranking of alternatives can also change. Within the ranges shown in 
Table 12, the values of the decision variables (    ) remain unchanged, but the value of    may change, depending on whether the 
variables associated with the coefficients are basic or nonbasic. If a variable is nonbasic, then the value of the
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coefficient can vary within the range shown in Table 12 and not affect the value of    or the final 
ranking of alternatives. The ranges highlighted in Table 12 are associated with nonbasic 
variables. For these ranges, the summation of the decision makers’ preferences can vary within 
this range and not change the value of    or the final ranking of alternatives.  
To understand how the final ranking of alternatives might also be affected by the weight of 
the decision makers, sensitivity analysis was performed to determine how a single decision 
maker’s weight can vary such that the ranking of a single vaccine candidate will remain the 
same. As an example, the weight of ‘Health Agency Representative’ was analyzed to see how it 
can vary such that the ranking of ‘Chlamydia’ will remain the same. A vaccine candidate’s 
ranking will remain the same if the weight associated with it is greater than the weight of the 
vaccine candidate ranked below it and less than the weight of the vaccine candidate ranked 
above it. In this case, the weight of ‘Chlamydia’ must be greater than or equal to 0.1061 and less 
than or equal to 0.1483 to remain the same.  
To determine the range for which the weight of ‘Health Agency Representative’ can vary 
such that the ranking of ‘Chlamydia’ will remain the same, equations 12 and 13 were solved.  
                                                         ∑                  
 
     ≤                                      (12)                  
                                                               ∑                  
 
      ≥                                     (13) 
      The functions for each criterion (   ) and for ‘Chlamydia’ with respect to each criterion 
(              ) were rewritten in terms of the values associated with those functions and 
              . Each equation was solved for                which represents the value that can be 
added to or subtracted from the weight of ‘Health Agency Representative’ such that the ranking 
of ‘Chlamydia’ will remain the same.  The calculations associated with solving these equations 
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can be found in Appendix K. The results of the analysis suggest that the weight of ‘Health 
Agency Representative’ can vary between 0 and 0.321654 without affecting the final ranking of 
‘Chlamydia’. A large range would suggest that ‘Health Agency Representative’ has little to no 
influence over the ranking of ‘Chlamydia’, while a small range would suggest that ‘Health 
Agency Representative’ has a significant influence over the ranking of ‘Chlamydia’. In this case, 
‘Health Agency Representative’ has a small influence over the ranking of ‘Chlamydia’.  
 
6. Conclusions 
The Comprehensive DEA Methodology for Priority Determination in the Group AHP 
(CDEAGAHP) does an effective job of calculating decision maker weights, criterion weights, 
and weights for each project with respect to each criterion to come up with a final weight for 
each project. The CDEAGAHP provides a methodology for calculating decision maker weights 
using the members of the group in an anonymous manner which is essential to preserving the 
integrity of the group decision making process. The methodology can be applied to any multiple 
criteria decision making (MCDM) problem that involves multiple decision makers evaluating 
multiple alternatives and assessing them according to a variety of quantitative and qualitative 
criteria. Examples of MCDM problems the methodology can be applied to include choosing a 
new vehicle for a company to purchase or identifying which vaccine candidates should receive 
increased attention and funding around the world. The rankings generated by the model are 





Future work related to this problem includes evaluating alternative methods for incorporating 
quantitative data into the model. Presently, quantitative data is gathered about each project with 
respect to a particular criterion and the projects are ranked according to how they perform with 
respect to that criterion. That ranking is then used to generate the pairwise comparison matrix for 
all of the decision makers. Alternative methods could be used to incorporate this data. 
For the vaccine prioritization problem specifically, testing the model with more decision 
makers, criteria, and vaccine candidates will provide a better understanding of how the model 
behaves when these conditions change. Additionally, collaboration with committee members of 
the 2012 IOM model committee could provide insight to other aspects of the vaccine 
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Appendix A: Vehicle Experiment 
The purpose of this experiment was to ensure that the DEA methodology for priority 
determination in the group AHP can be extended to include the determination of decision maker 
weights. This experiment serves as an illustrative example of the proposed methodology and 
demonstrates how the methodology can be applied to other problems with multiple criteria and 
decision makers. The methodology explained in Section 3.4 is used to calculate the weights of 
the decision makers, criteria, and alternatives.  
For the experiment, six groups of 5-9 individuals were asked to participate in a study that 
involved ranking vehicle choices. Each person was told that they were an employee working for 
a company that was considering the purchase of a vehicle for its sales team to use for business 
trips. Each person was randomly assigned a role in the company and was given a packet of 
information with eight vehicles to choose from. They were told that the company wanted to 
include members from all levels of the organization, so the roles within the company included: 
Chief Financial Officer, Human Resources Manager, Assembly Line Worker, Assembly Line 
Supervisor, Sales Team Manager, and multiple Sales Team Representatives. In the packet of 
information, the following information was provided about each vehicle: price, mileage, gas 
mileage, body style, exterior color, features, and pictures of the exterior and interior of the car. 
The eight vehicles were: a 2009 Ford F150 XLT, a 2013 Chrysler Town & Country Limited, a 
2012 Jeep Grand Cherokee Laredo, a 2012 Toyota Camry SE, a 2002 Nissan Altima 2.5 S, a 
2006 Dodge Grand Caravan SE, a 2012 Chevrolet Silverado 1500 LT, and a 2006 Honda CR-V 






































Price $17,994 $38,646 $25,991 $22,700 $5,995 $7,988 $27,869 $13,995 
Mileage 49,832 
mi. 
12 mi. 29,288 
mi. 



















































Pickup Minivan SUV Sedan Sedan Minivan Pickup SUV 
 
After reviewing the details about each car for a certain period of time, the individuals 
were asked to, as a group, rank the vehicles in order of which they thought the company should 
consider purchasing them. The individuals were informed that in addition to cost, the company 
would like them to consider comfort, durability, and the impression the vehicle will make when 
choosing which one to purchase. The first position in the ranking was for the vehicle the 
company should give the most consideration to for purchasing, while the last position in the 
ranking was for the vehicle the company should give the least consideration to for purchasing. If 
the group decided that two or more vehicles were equal in rank, they were able to rank them in 
the same position. Table 2 shows the resulting ranking for Group 1. The rankings for the rest of 




Table 2: Group 1 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2006 Honda CR-V SE 
4) 2002 Nissan Altima 2.5 S 
5) 2006 Dodge Grand Caravan SE 
6) 2013 Chrysler Town & Country Limited 
7) 2012 Chevrolet Silverado 1500 LT, 2009 Ford F150 XLT 
 
Following this activity, each member of the group was asked to independently fill out a 
packet that had them rank the decision makers, criteria of evaluation, and vehicles in comparison 
to the criteria. These rankings were requested to provide the information necessary to generate 
the pairwise comparison matrices for the model.  
First, each decision maker had to rank all of the decision makers, including him or 
herself, in order of ability to choose a vehicle for the company to purchase. For the ranking, the 
first position was for the decision maker with the most ability to choose a vehicle for the 
company to purchase, while the ninth position was for the decision maker with the least ability to 
choose a vehicle for the company to purchase. If someone thought that two or more decision 
makers were equal in rank, they could rank them in the same position. Before the ranking, each 
individual had to explain their experience with purchasing vehicles, so when they had to record 
their ranking of decision makers, they had to consider an individual’s experience with purchasing 
vehicles in addition to an individual’s position in the company.  
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After ranking the decision makers, each person had to rank the criteria of evaluation in 
order of importance in choosing a vehicle for the company to purchase. The criteria of evaluation 
were: gas mileage, color, cost, body style, make, appearance, features, and mileage. For the 
ranking, the first position was for the criterion that was most important to consider when 
choosing a vehicle for the company to purchase, while the eighth position was for the criterion 
that was least important to consider when choosing a vehicle for the company to purchase. If two 
or more criteria were considered equal in importance, a decision maker could rank them in the 
same position.  
Lastly, the decision makers were asked to rank the vehicles in order of preference for the 
qualitative criteria (color, body style, make, appearance, and features). For these rankings, the 
first position was for the vehicle that the decision maker thought best satisfied that criterion, 
while the eighth position was for the vehicle that the decision maker thought least satisfied that 
criterion. If two or more vehicles were considered equal in satisfying a certain criterion, a 
decision maker could rank them in the same position.  
The rankings provided by each decision maker were used to generate the pairwise 
comparison matrices for the model. Typically, decision makers would create pairwise 
comparison matrices themselves rather than record rankings of the decision makers, criteria, and 
alternatives, but constructing pairwise comparison matrices is a cumbersome task for decision 
makers when more than a few criteria are considered. In an effort to provide decision makers 
with an easy and quick method for identifying their preferences, the decision makers ranked their 
preferences, (as described above), so pairwise comparison matrices could be generated later. The 
pairwise comparison matrices were created according to the following rules: 1)     is an integer 
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valued 1-9, 2)     = 1/   , 3)    = 1 for all i, 3) if the rank of option i,   , and the rank of option j, 
  , were equal, then element     and     equaled one, 4) if    >   , then aij equaled (  –   + 1).  
For the quantitative criteria ‘cost’ and ‘mileage’, the vehicles were ranked in ascending 
order, and for the quantitative criteria ‘gas mileage’, the vehicles were ranked in descending 
order. The resulting rankings were then used to generate the appropriate pairwise comparison 
matrices using the method described above.  
Table 3 shows the weight assigned to each decision maker for Group 1, as determined by 
the model and the rankings provided by all of the decision makers. The weights assigned to each 
decision maker for the rest of the groups can be found in Appendix C. 
Table 3: Group 1 Decision Maker Weights 
Decision Maker Weight 
Sales Team Representative 0.205 
Sales Team Manager 0.161 
Sales Team Representative 0.134 
Assembly Line Supervisor 0.122 
Assembly Line Worker 0.110 
Sales Team Representative 0.103 
Chief Financial Officer 0.100 
Sales Team Representative 0.070 
Human Resources Manager 0.049 
 
When the decision makers were ranking the decision makers in the group, they were 
considering an individual’s role within the company along with their experience with purchasing 
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vehicles. This is evident by the resulting decision maker weights. In most cases, the individuals 
with the most weight were a) part of the sales team, the group that would be using the new 
vehicle, or b) the ones who seemed to have the most experience with vehicles based on the group 
discussions. The individuals with the least weight seemed to have a lesser knowledge of vehicles 
based on the group discussions, causing their peers to rank them low on their individual 
assessments, regardless of their position in the company. This in turn resulted in them receiving 
the least amount of influence in determining which vehicle the company should purchase.  
Table 4 shows the weight assigned to each criterion for Group 1, as determined by the 
rankings provided by all of the decision makers. The weights assigned to each criterion for the 
rest of the groups can be found in Appendix D. 
Table 4: Group 1 Criterion Weights 
Criterion Weight 
Gas Mileage 0.235 
Cost 0.185 
Mileage 0.173 








For most of the groups, ‘gas mileage’, ‘cost’, and ‘mileage’ were given higher 
consideration to than the other criteria, while ‘color’, ‘features’, and ‘make’ were given less 
consideration to than the other criteria.  
Table 5 shows the ranking of vehicles produced by the model for Group 1. The ranking 
of vehicles produced by the model for the rest of the groups can be found in Appendix E. 
Table 5: Group 1 Model Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
For most groups, a few differences existed between the ranking that resulted from the 
model and the ranking that resulted from the group discussions. Changes in a vehicle’s ranking 
occurred when the model needed to identify which vehicles performed best according to the 
criteria that the decision makers determined to be significant. The ranking of the 2002 Nissan 
Altima usually changed between the two rankings for this reason. For the group rankings, 
decision makers would rank the Altima low due to its age and appearance. When it came to the 
model ranking, though, decision makers frequently chose ‘cost’ and ‘gas mileage’ as top criteria. 
Because the Altima is number one in terms of cost and number three in terms of gas mileage, it 
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frequently moved up in rank between the group and model rankings. In these instances, the 
model was simply accounting for the criteria that the decision makers determined to be 
significant.  
Lastly, the k-means clustering algorithm [16] was used to sort the vehicles into clusters 
and identify which vehicles were similar in overall performance according to the final ranking. 
Tables 6 through 9 show the clusters that result from applying the k-means algorithm to Group 
1’s results with k = 2 to k = 5. The results of k-means clustering for the other groups can be 
found in Appendices F-J.  
Table 6: Group 1 K-means clustering: k = 2 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table 7: Group 1 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE 
7) 2012 Chevrolet Silverado 1500 LT 






Table 8: Group 1 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table 9: Group 1 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
The clustering of the Group 1 vehicles shows that there is not a significant difference 
between the ranking of the 2006 Honda CR-V and 2002 Nissan Altima, but there is a significant 










Appendix B: Vehicle Example Group Vehicle Rankings  
Table B1: Group 2 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2013 Chrysler Town & Country Limited 
4) 2006 Honda CR-V SE, 2006 Dodge Grand Caravan SE 
5) 2012 Chevrolet Silverado 1500 LT 
6) 2002 Nissan Altima 2.5 S 
7) 2009 Ford F150 XLT 
 
Table B2: Group 3 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2006 Honda CR-V SE 
3) 2006 Dodge Grand Caravan SE 
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2002 Nissan Altima 2.5 S 
7) 2012 Chevrolet Silverado 1500 LT, 2009 Ford F150 XLT 
 
Table B3: Group 4 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2006 Honda CR-V SE 
4) 2002 Nissan Altima 2.5 S 
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5) 2006 Dodge Grand Caravan SE 
6) 2013 Chrysler Town & Country Limited 
7) 2009 Ford F150 XLT 
8) 2012 Chevrolet Silverado 1500 LT 
 
Table B4: Group 5 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2006 Honda CR-V SE 
4) 2006 Dodge Grand Caravan SE 
5) 2002 Nissan Altima 2.5 S 
6) 2013 Chrysler Town & Country Limited 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table B5: Group 6 Vehicle Ranking 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2013 Chrysler Town & Country Limited 
4) 2006 Honda CR-V SE 
5) 2002 Nissan Altima 2.5 S 
6) 2006 Dodge Grand Caravan SE 




Appendix C: Vehicle Example Decision Maker Weights 
Table C1: Group 2 Decision Maker Weights 
Decision Maker Weight 
Sales Team Representative 0.203857 
Assembly Line Supervisor 0.178611 
Sales Team Representative 0.147251 
Sales Team Representative 0.139284 
Human Resources Manager 0.137797 
Sales Team Manager 0.105846 
Sales Team Representative 0.0490293 
Assembly Line Worker 0.0430622 
Chief Financial Officer 0.0348999 
 
Table C2: Group 3 Decision Maker Weights 
Decision Maker Weight 
Chief Financial Officer 0.219524 
Sales Team Representative 0.173396 
Sales Team Representative 0.165258 
Assembly Line Supervisor 0.122575 
Human Resources Manager 0.119295 
Sales Team Manager 0.108542 
Assembly Line Worker 0.101119 




Table C3: Group 4 Decision Maker Weights 
Decision Maker Weight 
Sales Team Manager 0.166367 
Chief Financial Officer 0.164945 
Human Resources Manager 0.160456 
Sales Team Representative 0.13028 
Sales Team Representative 0.12123 
Sales Team Representative 0.118721 
Sales Team Representative 0.113491 
Assembly Line Supervisor 0.113004 
Assembly Line Worker 0.0497484 
 
Table C4: Group 5 Decision Maker Weights 
Decision Maker Weight 
Sales Team Manager 0.288403 
Chief Financial Officer 0.192078 
Human Resources Manager 0.150424 
Sales Team Representative 0.134789 
Sales Team Representative 0.121699 
Sales Team Representative 0.107403 
Assembly Line Supervisor 0.0461601 






Table C5: Group 6 Decision Maker Weights 
Decision Maker Weight 
Chief Financial Officer 0.319642 
Sales Team Representative 0.281548 
Sales Team Manager 0.200677 
Sales Team Representative 0.191439 




















Appendix D: Vehicle Example Criterion Weights 





Gas Mileage 0.153486 





Table D2: Group 3 Criterion Weights 
Criterion Weight 
Cost 0.211628 
Gas Mileage 0.193846 
Mileage 0.181939 
Appearance 0.125923 












Gas Mileage 0.185236 
Mileage 0.176551 





Table D4: Group 5 Criterion Weights 
Criterion Weight 













Table D5: Group 6 Criterion Weights 
Criterion Weight 
Body Style 0.261357 
Mileage 0.202141 
Appearance 0.173748 



















Appendix E: Vehicle Example Model Vehicle Ranking 
Table E1: Group 2 Model Vehicle Ranking 
Vehicle Weight 
1) Toyota 0.21226 
2) Jeep 0.162489 
3) Nissan 0.1478 
4) Chrysler 0.145391 
5) Honda 0.137473 
6) Chevy 0.125838 
7) Dodge 0.116254 
8) Ford 0.0961831 
 
Table E2: Group 3 Model Vehicle Ranking 
Vehicle Weight 
1) Toyota 0.234231 
2) Nissan 0.167109 
3) Honda 0.159574 
4) Chrysler 0.147843 
5) Dodge 0.138073 
6) Jeep 0.117067 
7) Chevy 0.102084 





Table E3: Group 4 Model Vehicle Ranking 
Vehicle Weight 
1) Toyota 0.233732 
2) Nissan 0.176567 
3) Jeep 0.16396 
4) Chrysler 0.158372 
5) Honda 0.157053 
6) Chevy 0.120783 
7) Dodge 0.117781 
8) Ford 0.0891504 
 
Table E4: Group 5 Model Vehicle Ranking 
Vehicle Weight 
1) Toyota 0.241221 
2) Nissan 0.161906 
3) Honda 0.149379 
4) Chrysler 0.139058 
5) Jeep 0.126731 
6) Dodge 0.114109 
7) Chevy 0.110166 







Table E5: Group 6 Model Vehicle Ranking 
Vehicle Weight 
1) Toyota 0.220474 
2) Nissan 0.152795 
3) Jeep 0.148616 
4) Chrysler 0.136919 
5) Honda 0.136383 
6) Chevy 0.135783 
7) Dodge 0.0940066 

















Appendix F: Vehicle Example Group 2 k-means Clustering 
Table F1: Group 2 K-means clustering: k = 2 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 
8) 2009 Ford F150 XLT 
 
Table F2: Group 2 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 
8) 2009 Ford F150 XLT 
 
Table F3: Group 2 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 







Table F4: Group 2 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2012 Jeep Grand Cherokee Laredo 
3) 2002 Nissan Altima 2.5 S 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 





















Appendix G: Vehicle Example Group 3 k-means Clustering 
Table G1: Group 3 K-means clustering: k = 2 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Dodge Grand Caravan SE 
6) 2012 Jeep Grand Cherokee Laredo 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table G2: Group 3 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Dodge Grand Caravan SE 
6) 2012 Jeep Grand Cherokee Laredo 
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table G3: Group 3 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Dodge Grand Caravan SE 
6) 2012 Jeep Grand Cherokee Laredo 
7) 2012 Chevrolet Silverado 1500 LT 







Table G4: Group 3 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Dodge Grand Caravan SE 
6) 2012 Jeep Grand Cherokee Laredo 
7) 2012 Chevrolet Silverado 1500 LT 





















Appendix H: Vehicle Example Group 4 k-means Clustering 
Table H1: Group 4 K-means clustering: k = 2 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 
8) 2009 Ford F150 XLT 
 
Table H2: Group 4 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 
8) 2009 Ford F150 XLT 
 
Table H3: Group 4 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 







Table H4: Group 4 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo 
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT 
7) 2006 Dodge Grand Caravan SE 






















Appendix I: Vehicle Example Group 5 k-means Clustering 
Table I1: Group 5 K-means clustering: k = 2 
9) 2012 Toyota Camry SE 
10) 2002 Nissan Altima 2.5 S 
11) 2006 Honda CR-V SE  
12) 2013 Chrysler Town & Country Limited 
13) 2012 Jeep Grand Cherokee Laredo 
14) 2006 Dodge Grand Caravan SE  
15) 2012 Chevrolet Silverado 1500 LT 
16) 2009 Ford F150 XLT 
 
Table I2: Group 5 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE  
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE  
7) 2012 Chevrolet Silverado 1500 LT 
8) 2009 Ford F150 XLT 
 
Table I3: Group 5 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE  
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE  
7) 2012 Chevrolet Silverado 1500 LT 







Table I4: Group 5 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2006 Honda CR-V SE  
4) 2013 Chrysler Town & Country Limited 
5) 2012 Jeep Grand Cherokee Laredo 
6) 2006 Dodge Grand Caravan SE  
7) 2012 Chevrolet Silverado 1500 LT 





















Appendix J: Vehicle Example Group 6 k-means Clustering 
Table J1: Group 6 K-means clustering: k = 2 
17) 2012 Toyota Camry SE 
18) 2002 Nissan Altima 2.5 S 
19) 2012 Jeep Grand Cherokee Laredo  
20) 2013 Chrysler Town & Country Limited 
21) 2006 Honda CR-V SE 
22) 2012 Chevrolet Silverado 1500 LT  
23) 2006 Dodge Grand Caravan SE 
24) 2009 Ford F150 XLT 
 
Table J2: Group 6 K-means clustering: k = 3 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo  
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT  
7) 2006 Dodge Grand Caravan SE 
8) 2009 Ford F150 XLT 
 
Table J3: Group 6 K-means clustering: k = 4 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo  
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT  
7) 2006 Dodge Grand Caravan SE 







Table J4: Group 6 K-means clustering: k = 5 
1) 2012 Toyota Camry SE 
2) 2002 Nissan Altima 2.5 S 
3) 2012 Jeep Grand Cherokee Laredo  
4) 2013 Chrysler Town & Country Limited 
5) 2006 Honda CR-V SE 
6) 2012 Chevrolet Silverado 1500 LT  
7) 2006 Dodge Grand Caravan SE 





















Appendix K: Sensitivity Analysis Calculation 
 
Final weight of Alternative    =   ∑         
 
    
           = 0.1293 
0.1061 ≤            ≤ 0.1483 
 
            ≥ (                                        )  + 
(                                                      ) + 
(                                                 ) + (                                                ) 
+ (                                      ) + (                                 (                    ) + 
(                                                  ) + 
(                                                          ) + 
(                                                 + (                                    
0.1483 ≥  
(0.174248776 +                  (0.20745582))(0.094918693 +                  (0.08454348)) +  
(0.100617054 +                  (0.120296914))(0.105894635 +                  (0.08376367)) +  
(0.027392656 +                  (0.038151967))(0.052969646 +                  (0.09016668)) + 
 (0.17421749 +                  (0.20829227))(0.120315309 +                  (0.08301262)) +  
(0.052596999 +                  (0.062884365))(0.076275375 +                  (0.04572506)) + 
 (0.075880705 +                  (0.0907221))(0.09001065 +                  (0.08642504)) +  
(0.01607623 +                  (0.01922052))(0.136847309 +                  (0.08301262)) +  
(0.052125907 +                  (0.054869718))(0.049243159 +                  (0.02734054)) +  
(0.173912778 +                  (0.207928445))(0.093882309 +                  (0.08301262)) + 







0.0165394661 + (0.0147315979)                  + (0.0196914353)                  + 
(0.017539037)                 
2 + 
0.0106548062 + (0.0084280537)                  + (0.0127387978)                  + 
(0.010076511)                 
2 + 
0.0014509793 + (0.0024699048)                  + (0.0020208962)                  + 
(0.0034400362)                 
2 + 
0.0209610311 + (0.0144622503)                  + (0.0250607488)                  + 
(0.0172908871                
2 + 
0.0040118558 + (0.0024050009)                  + (0.0047965285)                  + 
(0.0028753914)                 
2 + 
0.0068300716 + (0.006557993)                  + (0.0081659552)                  + 
(0.0078406611)                 
2 + 
0.0021999888 + (0.00133453)                  + (0.0026302764)                  + 
(0.0015955457)                 
2 + 
0.0025668443 + (0.0014251504)                  + (0.0027019582)                  + 
(0.0015001677)                 
2 + 
0.0163273332 + (0.0144369554)                  + (0.0195208025)                  + 
(0.017260685)                 
2 + 
0.0054109594 + (0.0056054798)                  + (0.0064692834)                  + 
(0.0067018498)                 
2 
     
0.1483 ≥ 0.0869533358 + (0.0718569162)                  + (0.1037966823)                  + 
(0.086120772)                 
2 
 
0.1483 ≥ 0.0869533358 + (0.1756535985)                  + (0.086120772)                 
2 
(0.086120772)                 
2 + (0.1756535985)                  – 0.0613466642 ≤ 0 




0.1061 ≤ 0.0869533358 + (0.1756535985)                  + (0.086120772)                 
2 
(0.086120772)                 
2 + (0.1756535985)                  – 0.0191466642 ≥ 0 
               = -2.1433466462, 0.1037272324 
 
               = 0.217927 
0.217927 – 2.34357 < xHA <  0.217927 + 0.103727 
0 <                <  0.321654 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
